Show simple item record

dc.contributor.authorAhola, Terhi
dc.contributor.authorLapatto, Risto
dc.contributor.authorRaivio, Kari O
dc.contributor.authorSelander, Bo
dc.contributor.authorStigson, Lennart
dc.contributor.authorJonsson, Baldvin
dc.contributor.authorJonsbo, Finn
dc.contributor.authorEsberg, Gitte
dc.contributor.authorStövring, Sören
dc.contributor.authorKjartansson, Sveinn
dc.contributor.authorStiris, Tom
dc.contributor.authorLossius, Kristin
dc.contributor.authorVirkola, Kristina
dc.contributor.authorFellman, Vineta
dc.date.accessioned2006-09-25T09:14:12Z
dc.date.available2006-09-25T09:14:12Z
dc.date.issued2003-12-01
dc.identifier.citationJ. Pediatr. 2003, 143(6):713-9en
dc.identifier.issn0022-3476
dc.identifier.pmid14657813
dc.identifier.doidoi:10.1067/S0022-3476(03)00419-0
dc.identifier.otherPED12
dc.identifier.urihttp://hdl.handle.net/2336/4585
dc.description.abstractOBJECTIVE: To evaluate whether N-acetylcysteine (NAC) infusion during the first week of life reduces the risk of death or bronchopulmonary dysplasia (BPD) in infants with extremely low birth weight.Study design In a Nordic multicenter, double-blind trial, infants (n=391) weighing 500 to 999 g and on ventilator or nasal continuous positive airway pressure were randomized before the age of 36 hours to receive NAC 16 to 32 mg/kg/d (n=194) or placebo (n=197) intravenously for 6 days. Primary end points were death or BPD, defined as supplementary oxygen requirement at 36 weeks' gestational age. RESULTS: There was no difference in the combined incidence of the primary end points death or BPD, 51% vs. 49%, between the NAC group and control group. Also similar was the incidence of BPD in survivors at 36 weeks' gestational age, 40% vs. 40%, and the mean oxygen requirement at the age of 28 days, 31.2% vs. 30.7%, respectively. The severity of BPD was similar in both groups. CONCLUSIONS: A 6-day course of intravenous N-acetylcysteine at the dosage used does not prevent BPD or death in infants with extremely low birth weight.
dc.language.isoenen
dc.publisherMosbyen
dc.relation.urlhttp://dx.doi.org/10.1067/S0022-3476(03)00419-0en
dc.subject.meshAntioxidantsen
dc.subject.meshBronchopulmonary Dysplasiaen
dc.subject.meshCystineen
dc.subject.meshDouble-Blind Methoden
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshInfant, Newbornen
dc.subject.meshInfant, Prematureen
dc.subject.meshInfant, Very Low Birth Weighten
dc.subject.meshInfusions, Intravenousen
dc.subject.meshMaleen
dc.subject.meshResearch Support, Non-U.S. Gov'ten
dc.titleN-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trialen
dc.typeArticleen
dc.format.digYES
html.description.abstractOBJECTIVE: To evaluate whether N-acetylcysteine (NAC) infusion during the first week of life reduces the risk of death or bronchopulmonary dysplasia (BPD) in infants with extremely low birth weight.Study design In a Nordic multicenter, double-blind trial, infants (n=391) weighing 500 to 999 g and on ventilator or nasal continuous positive airway pressure were randomized before the age of 36 hours to receive NAC 16 to 32 mg/kg/d (n=194) or placebo (n=197) intravenously for 6 days. Primary end points were death or BPD, defined as supplementary oxygen requirement at 36 weeks' gestational age. RESULTS: There was no difference in the combined incidence of the primary end points death or BPD, 51% vs. 49%, between the NAC group and control group. Also similar was the incidence of BPD in survivors at 36 weeks' gestational age, 40% vs. 40%, and the mean oxygen requirement at the age of 28 days, 31.2% vs. 30.7%, respectively. The severity of BPD was similar in both groups. CONCLUSIONS: A 6-day course of intravenous N-acetylcysteine at the dosage used does not prevent BPD or death in infants with extremely low birth weight.


This item appears in the following Collection(s)

Show simple item record